These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 7895348

  • 1. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
    Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM.
    Circulation; 1995 Apr 01; 91(7):1923-8. PubMed ID: 7895348
    [Abstract] [Full Text] [Related]

  • 2. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators.
    N Engl J Med; 1993 Nov 25; 329(22):1615-22. PubMed ID: 8232430
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T, Hermens WT, Lenderink T, Molhoek GP, Grollier G, Pfisterer M, Simoons ML.
    Eur Heart J; 1996 Feb 25; 17(2):237-46. PubMed ID: 8732377
    [Abstract] [Full Text] [Related]

  • 4. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
    Singh N, Mironov D, Armstrong PW, Ross AM, Langer A.
    Circulation; 1996 Apr 01; 93(7):1388-95. PubMed ID: 8641028
    [Abstract] [Full Text] [Related]

  • 5. TIMI grade flow, mortality, and the GUSTO-III trial.
    Stringer KA.
    Pharmacotherapy; 1998 Apr 01; 18(4):699-705. PubMed ID: 9692644
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM.
    JAMA; 1996 Mar 13; 275(10):777-82. PubMed ID: 8598594
    [Abstract] [Full Text] [Related]

  • 11. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Langer A, Krucoff MW, Klootwijk P, Veldkamp R, Simoons ML, Granger C, Califf RM, Armstrong PW.
    J Am Coll Cardiol; 1995 Jun 13; 25(7):1552-7. PubMed ID: 7759706
    [Abstract] [Full Text] [Related]

  • 12. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators.
    N Engl J Med; 1993 Sep 02; 329(10):673-82. PubMed ID: 8204123
    [Abstract] [Full Text] [Related]

  • 13. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
    Goodman SG, Langer A, Ross AM, Wildermann NM, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Califf RM, Topol EJ, Simoons ML, Armstrong PW.
    Circulation; 1998 Feb 10; 97(5):444-50. PubMed ID: 9490238
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG, Laperche T, Golmard JL, Juliard JM, Benamer H, Himbert D, Aubry P.
    J Am Coll Cardiol; 1998 Mar 15; 31(4):776-9. PubMed ID: 9525545
    [Abstract] [Full Text] [Related]

  • 15. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
    White HD.
    Am J Cardiol; 1998 Oct 22; 82(8B):57P-62P. PubMed ID: 9809893
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Gender and acute myocardial infarction: is there a different response to thrombolysis?
    Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM.
    J Am Coll Cardiol; 1997 Jan 22; 29(1):35-42. PubMed ID: 8996292
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.